Vaxil BioTherapeutics Ltd.- PR-2012

Press Release- 2012

Nes-Ziona, 26^th Dec, 2012. Vaxil BioTherapeutics announces that it has recruited three additinal patients for its follow on trial- VAXIL-002.
Read More

For further details see the attached PDF file.

Nes-Ziona, 20^th Dec, 2012. Vaxil BioTherapeutics announces approval by the Israeli Chief Scientist of a 3 million NIS program for the further development of Vaxil's therapeutic cancer vaccine ImMucin for Multiple Myeloma Read More

For further details see the attached PDF file.

Nes-Ziona, 04^th Sep, 2012. Vaxil BioTherapeutics announces that it has recruited the first two patients for its follow on trial- VAXIL-002. Read More

For further details see the attached PDF file.

Nes-Ziona, 14^th Aug, 2012. Vaxil BioTherapeutics reports that it has finished recruitment of all the patients for the VAXIL-001 clinical trial.
Read More

For further details see the attached PDF file.

Nes-Ziona, 30^th July, 2012. Vaxil Biotherapeutics announced the begininig of a follow up trial- VAXIL-002.
Read More

For further details see the attached PDF file.

Nes-Ziona, 22^nd July, 2012. Vaxil Biotherapeutics completed the merger of its activities with Sheldonco Ltd.
Read More

For further details see the attached PDF file.

Nes-Ziona, 2^nd April, 2012. Vaxil Biotherapeutics Ltd. announced today positive interim results from its Phase I/II therapeutic cancer vaccine trial in Multiple Myeloma patients.
Read More

For further details
see the attached PDF file.

Nes-Ziona, 21^st February, 2012. Vaxil Biotherapeutics Ltd. announced today that it has signed a definitive agreement to merge its activities into Sheldonco Ltd, a company traded on the Tel Aviv Stock Exchange (TASE).
Read More

For further details see the attached PDF file.